Multidisciplinary Strategies to Enhance Therapeutic Effects of Flavonoids from Epimedii Folium: Integration of Herbal Medicine, Enzyme Engineering, and Nanotechnology

Overview

Journal J Pharm Anal

Specialty Chemistry

Date 2023 Apr 27

PMID 37102112

Authors

Yi Lu

Qiulan Luo

Xiaobin Jia

James P Tam

Huan Yang

Yuping Shen

Xin Li

Affiliations

Soon will be listed here.

Abstract

Flavonoids such as baohuoside I and icaritin are the major active compounds in Epimedii Folium (EF) and possess excellent therapeutic effects on various diseases. Encouragingly, in 2022, icaritin soft capsules were approved to reach the market for the treatment of hepatocellular carcinoma (HCC) by National Medical Products Administration (NMPA) of China. Moreover, recent studies demonstrate that icaritin can serve as immune-modulating agent to exert anti-tumor effects. Nonetheless, both production efficiency and clinical applications of epimedium flavonoids have been restrained because of their low content, poor bioavailability, and unfavorable in vivo delivery efficiency. Recently, various strategies, including enzyme engineering and nanotechnology, have been developed to increase productivity and activity, improve delivery efficiency, and enhance therapeutic effects of epimedium flavonoids. In this review, the structure-activity relationship of epimedium flavonoids is described. Then, enzymatic engineering strategies for increasing the productivity of highly active baohuoside I and icaritin are discussed. The nanomedicines for overcoming in vivo delivery barriers and improving therapeutic effects of various diseases are summarized. Finally, the challenges and an outlook on clinical translation of epimedium flavonoids are proposed.

Citing Articles

Choline Carboxylic Acid Ionic Liquid-stabilized Anisotropic Gold Nanoparticles for Photothermal Therapy.

Vashisth P, Smith C, Amarasekara D, Dasanyake G, Singh G, Chism C ACS Appl Nano Mater. 2025; 7(23):26332-26343.

PMID: 39935958 PMC: 11810124. DOI: 10.1021/acsanm.3c04645.

Chen's peiyuan tang and premature ovarian failure: unveiling the mechanisms through network pharmacology.

Yang X, Mao Y, Yao C, Song D, He Y, Shen W Front Pharmacol. 2024; 15:1446707.

PMID: 39679373 PMC: 11637857. DOI: 10.3389/fphar.2024.1446707.

Purification and immobilization of β-glucosidase using surface modified mesoporous silica Santa Barbara Amorphous 15 for eco-friendly preparation of sagittatoside A.

Yang Y, Jing S, Shao J, Chen J, Zhang W, Wan S Nat Prod Bioprospect. 2024; 14(1):50.

PMID: 39177672 PMC: 11343960. DOI: 10.1007/s13659-024-00471-x.

Small-molecule-based targeted therapy in liver cancer.

Ming Y, Gong Y, Fu X, Ouyang X, Peng Y, Pu W Mol Ther. 2024; 32(10):3260-3287.

PMID: 39113358 PMC: 11489561. DOI: 10.1016/j.ymthe.2024.08.001.

Disrupting redox homeostasis for tumor therapy based on PDT/chemo/ferroptosis therapeutic hybrid liposomes.

Huang Y, Liu H, Zhao Y, Chen H, Li Q, Li X RSC Adv. 2024; 14(28):20152-20162.

PMID: 38915327 PMC: 11195642. DOI: 10.1039/d4ra03361b.

References

Guo Y, Zhu H, Weng M, Chen B, Wang C, Sun L . Baohuoside-1 targeting mTOR inducing apoptsis to inhibit hepatocellular carcinoma proliferation, invasion and migration. Biomed Pharmacother. 2020; 128:110366. DOI: 10.1016/j.biopha.2020.110366. View

Shen R, Deng W, Li C, Zeng G . A natural flavonoid glucoside icariin inhibits Th1 and Th17 cell differentiation and ameliorates experimental autoimmune encephalomyelitis. Int Immunopharmacol. 2014; 24(2):224-231. DOI: 10.1016/j.intimp.2014.12.015. View

de Lazaro I, Mooney D . Obstacles and opportunities in a forward vision for cancer nanomedicine. Nat Mater. 2021; 20(11):1469-1479. DOI: 10.1038/s41563-021-01047-7. View

Zhai Y, Ge B, Chen K, Ma H, Ming L, Li Z . [Comparative study on the osteogenic differentiation of rat bone marrow stromal cells effected by icariin and icariside II]. Zhong Yao Cai. 2011; 33(12):1896-900. View

Pan X, Li L, Huang Y, Huang H, Xu D, Gao Y . Icaritin acts synergistically with epirubicin to suppress bladder cancer growth through inhibition of autophagy. Oncol Rep. 2015; 35(1):334-42. DOI: 10.3892/or.2015.4335. View

Ni F, Tang H, Wang C, Zhang H, Zheng C, Zhang N . Baohuoside I Inhibits the Proliferation of Pancreatic Cancer Cells via mTOR/S6K1-Caspases/Bcl2/Bax Apoptotic Signaling. Cancer Manag Res. 2020; 11:10609-10621. PMC: 6927568. DOI: 10.2147/CMAR.S228926. View

Chen X, Ji H, Zhang Q, Tu P, Wang Y, Guo B . A rapid method for simultaneous determination of 15 flavonoids in Epimedium using pressurized liquid extraction and ultra-performance liquid chromatography. J Pharm Biomed Anal. 2007; 46(2):226-35. DOI: 10.1016/j.jpba.2007.09.016. View

Hui-Rong X, Hui-Ping M, Ke-Ming C, Xiao-Shuan L . [Preparation and characterization of icariin nanosuspension and lyophilized powder]. Zhongguo Zhong Yao Za Zhi. 2020; 45(20):4902-4908. DOI: 10.19540/j.cnki.cjcmm.20200328.301. View

Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

10.

Chen X, Tang Z, Li X, Xie C, Lu J, Wang Y . Chemical Constituents, Quality Control, and Bioactivity of Epimedii Folium (Yinyanghuo). Am J Chin Med. 2015; 43(5):783-834. DOI: 10.1142/S0192415X15500494. View

11.

Tang Y, Li Y, Xin D, Chen L, Xiong Z, Yu X . Icariin alleviates osteoarthritis by regulating autophagy of chondrocytes by mediating PI3K/AKT/mTOR signaling. Bioengineered. 2021; 12(1):2984-2999. PMC: 8806900. DOI: 10.1080/21655979.2021.1943602. View

12.

Yang X, Xi Y, Li Z . Icaritin: A Novel Natural Candidate for Hematological Malignancies Therapy. Biomed Res Int. 2019; 2019:4860268. PMC: 6458936. DOI: 10.1155/2019/4860268. View

13.

Rawat S, Jain S . Solubility enhancement of celecoxib using beta-cyclodextrin inclusion complexes. Eur J Pharm Biopharm. 2004; 57(2):263-7. DOI: 10.1016/j.ejpb.2003.10.020. View

14.

Jin X, Zhang Z, Sun E, Qian Q, Tan X, Jia X . Preparation of a nanoscale baohuoside I-phospholipid complex and determination of its absorption: in vivo and in vitro evaluations. Int J Nanomedicine. 2012; 7:4907-16. PMC: 3446837. DOI: 10.2147/IJN.S35965. View

15.

Li Y, Sun S, Chang Q, Zhang L, Wang G, Chen W . A strategy for the improvement of the bioavailability and antiosteoporosis activity of BCS IV flavonoid glycosides through the formulation of their lipophilic aglycone into nanocrystals. Mol Pharm. 2013; 10(7):2534-42. DOI: 10.1021/mp300688t. View

16.

Wu H, Liu X, Gao Z, Lin M, Zhao X, Sun Y . Icaritin Provides Neuroprotection in Parkinson's Disease by Attenuating Neuroinflammation, Oxidative Stress, and Energy Deficiency. Antioxidants (Basel). 2021; 10(4). PMC: 8066334. DOI: 10.3390/antiox10040529. View

17.

Liu Y, Yang H, Xiong J, Zhao J, Guo M, Chen J . Icariin as an emerging candidate drug for anticancer treatment: Current status and perspective. Biomed Pharmacother. 2022; 157:113991. DOI: 10.1016/j.biopha.2022.113991. View

18.

Li C, Yang S, Ma H, Ruan M, Fang L, Cheng J . Influence of icariin on inflammation, apoptosis, invasion, and tumor immunity in cervical cancer by reducing the TLR4/MyD88/NF-κB and Wnt/β-catenin pathways. Cancer Cell Int. 2021; 21(1):206. PMC: 8045342. DOI: 10.1186/s12935-021-01910-2. View

19.

Song L, Chen X, Mi L, Liu C, Zhu S, Yang T . Icariin-induced inhibition of SIRT6/NF-κB triggers redox mediated apoptosis and enhances anti-tumor immunity in triple-negative breast cancer. Cancer Sci. 2020; 111(11):4242-4256. PMC: 7648025. DOI: 10.1111/cas.14648. View

20.

Tu L, Liao Z, Luo Z, Wu Y, Herrmann A, Huo S . Ultrasound-controlled drug release and drug activation for cancer therapy. Exploration (Beijing). 2023; 1(3):20210023. PMC: 10190934. DOI: 10.1002/EXP.20210023. View